Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

BACKGROUND: We assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refractory metastatic pancreatic cancer previously treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Melisi, Davide, Oh, Do-Youn, Hollebecque, Antoine, Calvo, Emiliano, Varghese, Anna, Borazanci, Erkut, Macarulla, Teresa, Merz, Valeria, Zecchetto, Camilla, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Gandhi, Leena, Estrem, Shawn T, Benhadji, Karim A, Lanasa, Mark C, Avsar, Emin, Guba, Susan C, Garcia-Carbonero, Rocio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944986/
https://www.ncbi.nlm.nih.gov/pubmed/33688022
http://dx.doi.org/10.1136/jitc-2020-002068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944986/
https://www.ncbi.nlm.nih.gov/pubmed/33688022
http://dx.doi.org/10.1136/jitc-2020-002068

Ejemplares similares